International Waldenstrom’s Macroglobulinemia Foundation




The IWMF is excited to share that the U.S. Food and Drug Administration (FDA) has approved the use of Zanubrutinib for the treatment of WM.

From IWMF Board Chair, Peter DeNardis:

“The approval of Brukinsa in Waldenström’s macroglobulinemia, which is the second therapy approved specifically for the treatment of this rare type of lymphoma, is positive news for patients. Expanded treatment options offer new hope for those living with this disease and can potentially improve patient experience, especially oral therapies that can be given as a single agent.”


  • 6144 Clark Center Ave.
    Sarasota, FL 34238
  • Phone: 941-927-4963
  • Fax: 941-927-4467
  • [email protected]